Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Fountain Valley, CA
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Los Angeles, CA
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Gainesville, FL
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Indianapolis, IN
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Lexington, KY
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
New Orleans, LA
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Shreveport, LA
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Shreveport, LA
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Scarborough, ME
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Scarborough, ME
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Springfield, MA
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Springfield, MA
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Duluth, MN
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Duluth, MN
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Minneapolis, MN
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Robbinsdale, MN
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Saint Louis, MO
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
St. Louis, MT
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
St. Louis, MT
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Albuquerque, NM
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Raleigh, NC
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Akron, OH
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Akron, OH
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Cincinnati, OH
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Cleveland, OH
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Toledo, OH
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Toledo, OH
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Fort Worth, TX
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
San Antonio, TX
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Green Bay, WI
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Green Bay, WI
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
La Crosse, WI
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
La Crosse, WI
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Madison, WI
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Milwaukee, WI
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Wausau, WI
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Wausau, WI
Click here to add this to my saved trials
Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer
A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation With Concurrent 5-Fluorouracil and Mitomycin-C for Stage I-III Carcinoma of the Anal Canal
Status: Enrolling
Updated:  5/31/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer
A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation With Concurrent 5-Fluorouracil and Mitomycin-C for Stage I-III Carcinoma of the Anal Canal
Status: Enrolling
Updated: 5/31/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase 1 Study of OTS167 in Patients With Solid Tumors
PhaseI, Single-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Preliminary Antineoplastic Activity of OTS167, a MELK Inhibitor, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies
Status: Enrolling
Updated:  5/31/2017
University of Chicago
mi
from
Chicago, IL
Phase 1 Study of OTS167 in Patients With Solid Tumors
PhaseI, Single-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Preliminary Antineoplastic Activity of OTS167, a MELK Inhibitor, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies
Status: Enrolling
Updated: 5/31/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage
Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage
Status: Enrolling
Updated:  6/1/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage
Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage
Status: Enrolling
Updated: 6/1/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers
Nueva Vida Intervention: Improving QOL in Latina Breast Cancer Survivors and Their Caregivers
Status: Enrolling
Updated:  6/2/2017
Latinas Contra Cancer
mi
from
San Jose, CA
Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers
Nueva Vida Intervention: Improving QOL in Latina Breast Cancer Survivors and Their Caregivers
Status: Enrolling
Updated: 6/2/2017
Latinas Contra Cancer
mi
from
San Jose, CA
Click here to add this to my saved trials
Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers
Nueva Vida Intervention: Improving QOL in Latina Breast Cancer Survivors and Their Caregivers
Status: Enrolling
Updated:  6/2/2017
Gilda's Club New York City
mi
from
New York, NY
Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers
Nueva Vida Intervention: Improving QOL in Latina Breast Cancer Survivors and Their Caregivers
Status: Enrolling
Updated: 6/2/2017
Gilda's Club New York City
mi
from
New York, NY
Click here to add this to my saved trials
Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers
Nueva Vida Intervention: Improving QOL in Latina Breast Cancer Survivors and Their Caregivers
Status: Enrolling
Updated:  6/2/2017
SHARE
mi
from
New York, NY
Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers
Nueva Vida Intervention: Improving QOL in Latina Breast Cancer Survivors and Their Caregivers
Status: Enrolling
Updated: 6/2/2017
SHARE
mi
from
New York, NY
Click here to add this to my saved trials
Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers
Nueva Vida Intervention: Improving QOL in Latina Breast Cancer Survivors and Their Caregivers
Status: Enrolling
Updated:  6/2/2017
Nueva Vida
mi
from
Washington, D.C.,
Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers
Nueva Vida Intervention: Improving QOL in Latina Breast Cancer Survivors and Their Caregivers
Status: Enrolling
Updated: 6/2/2017
Nueva Vida
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study
Status: Enrolling
Updated:  6/5/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study
Status: Enrolling
Updated: 6/5/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer
Tangential Radiation Therapy Without Axillary Dissection in Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/6/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer
Tangential Radiation Therapy Without Axillary Dissection in Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/6/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer
Tangential Radiation Therapy Without Axillary Dissection in Early-Stage Breast Cancer
Status: Enrolling
Updated:  6/6/2017
Massachusetts General Hospital
mi
from
Boston, MA
Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer
Tangential Radiation Therapy Without Axillary Dissection in Early-Stage Breast Cancer
Status: Enrolling
Updated: 6/6/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of Aspirin and Arginine Restriction in Colorectal Cancer
Phase IIA Clinical Biomarker Trial of Aspirin and Arginine Restriction in Colorectal Cancer Patients
Status: Enrolling
Updated:  6/7/2017
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Trial of Aspirin and Arginine Restriction in Colorectal Cancer
Phase IIA Clinical Biomarker Trial of Aspirin and Arginine Restriction in Colorectal Cancer Patients
Status: Enrolling
Updated: 6/7/2017
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors
An Open-Label Study to Characterize the Absorption, Distribution, Metabolism and Elimination of a Single Oral 14C Labeled Dose of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
Status: Enrolling
Updated:  6/7/2017
GSK Investigational Site
mi
from
Tacoma, WA
An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors
An Open-Label Study to Characterize the Absorption, Distribution, Metabolism and Elimination of a Single Oral 14C Labeled Dose of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
Status: Enrolling
Updated: 6/7/2017
GSK Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
Status: Enrolling
Updated:  6/7/2017
Clinical Research Facility
mi
from
Atlanta, GA
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
Status: Enrolling
Updated: 6/7/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
Status: Enrolling
Updated:  6/7/2017
Clinical Research Facility
mi
from
Seattle, WA
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
Status: Enrolling
Updated: 6/7/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
Status: Enrolling
Updated:  6/7/2017
mi
from
Rozzano,
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
Status: Enrolling
Updated: 6/7/2017
mi
from
Rozzano,
Click here to add this to my saved trials
SRS Study in Patients With Non-Small Cell Lung Cancer
Phase II Stereotactic Body Radiotherapy for Stage I (T1-T2, N0, M0), Selective Stage II (Chest Wall T3, N0M0) or Isolated Peripheral Lung Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/8/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
SRS Study in Patients With Non-Small Cell Lung Cancer
Phase II Stereotactic Body Radiotherapy for Stage I (T1-T2, N0, M0), Selective Stage II (Chest Wall T3, N0M0) or Isolated Peripheral Lung Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/8/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery
Cytopathologic Margin Evaluation in Patients Undergoing Pancreatic Cancer Resection
Status: Enrolling
Updated:  6/8/2017
Ohio State University Medical Center
mi
from
Columbus, OH
Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery
Cytopathologic Margin Evaluation in Patients Undergoing Pancreatic Cancer Resection
Status: Enrolling
Updated: 6/8/2017
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Open Label Study of BAY1082439 in Patients With Advanced Cancer
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  6/8/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Open Label Study of BAY1082439 in Patients With Advanced Cancer
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 6/8/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Open Label Study of BAY1082439 in Patients With Advanced Cancer
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  6/8/2017
Clinical Research Facility
mi
from
Dallas, TX
Open Label Study of BAY1082439 in Patients With Advanced Cancer
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 6/8/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Open Label Study of BAY1082439 in Patients With Advanced Cancer
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  6/8/2017
Clinical Research Facility
mi
from
Houston, TX
Open Label Study of BAY1082439 in Patients With Advanced Cancer
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 6/8/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Open Label Study of BAY1082439 in Patients With Advanced Cancer
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  6/8/2017
mi
from
Seoul,
Open Label Study of BAY1082439 in Patients With Advanced Cancer
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 6/8/2017
mi
from
Seoul,
Click here to add this to my saved trials
Open Label Study of BAY1082439 in Patients With Advanced Cancer
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  6/8/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Open Label Study of BAY1082439 in Patients With Advanced Cancer
An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 6/8/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Los Gatos, CA
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Los Gatos, CA
Click here to add this to my saved trials